Ingredient name record

Tranexamic Acid

Korean search label: 트라넥사믹애씨드

Evidence at a glance

2official function labelsIngredient context 2selected human studiesNot a full review

0selected legal receiptsNot a compliance verdict

Evidence coverage, not an efficacy or safety score.

Identity & coverage details

Official CosIng inventory context recorded; chemical identity and the complete current regulatory profile remain unverified; selected human studies available.

Recorded presence is not a safety rating, recommended dose or benefit claim.

Identity and formulation context

Names are indexed using case and whitespace normalization. Botanical, chemical and marketing identities have not been independently equated.

These are topical melasma treatment studies, distinct from oral or injected tranexamic acid and from unverified cosmetic brightening claims. Active comparators and different vehicles limit ingredient-only conclusions.

Discovery spellings and aliases

tranexamic · tranexamic acid · txa · 트라넥사믹 애씨드 · 트라넥사믹애씨드 · 트라넥사민 · 트라넥삼산 · 티엑스에이

Search-only metadata; an alias is not proof of chemical equivalence.

Functions listed by CosIng

ASTRINGENTSKIN CONDITIONING

Inventory functions describe the ingredient entry, not a finished product’s effects.

How this inventory match is used

The European Commission’s CosIng inventory is informational. An entry is not permission to use an ingredient or a safety assessment. Listed functions describe the inventory entry; they do not establish a finished product’s effects. The match uses the exact ingredient name, with case and whitespace normalization.

TRANEXAMIC ACID · Inventory identifiers

Inventory record: 80291 · Active
CAS identifiers in this entry: 1197-18-8
EC identifiers in this entry: 214-818-2

Checked 2026-10-02 · Read the official CosIng entry

Human study context

Primary publications checked 2026-10-03. These are selected studies, not a systematic review, safety rating or instructions for using a product.

A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma.

2019 · Original abstract reviewed

Material tested: 5% tranexamic acid solution versus 3% hydroquinone cream.
Study design: Prospective randomized single-blind active-comparator trial.
Participants: 100 analyzed patients: 84 women and 16 men; mixed, epidermal and dermal melasma.
Concentration and schedule in the study: 12 weeks; application frequency absent from the abstract.
What the authors reported: MASI decreased 27% and 26.7%, respectively, without significant between-group difference. Satisfaction favored the tranexamic group with fewer adverse effects.

What this does not establish

Solution and cream vehicles differ; no vehicle-only arm.
No significant difference is not proof of equivalence or a recommendation for cosmetic use.

Read the original publication

The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.

2024 · Original abstract reviewed

Material tested: 3% tranexamic acid cream versus 4% hydroquinone cream.
Study design: Double-blind, randomized split-face trial.
Participants: 20 subjects with mixed-type melasma in the Indonesian population.
Concentration and schedule in the study: Eight weeks; application frequency absent from the abstract.
What the authors reported: Both sides showed lower mMASI at weeks four and eight. Participant global ratings did not significantly differ.

What this does not establish

Very small trial; the abstract gives no numerical between-group mMASI effect.
The study does not establish safety for every person, other pigmentation conditions or long-term use.

Read the original publication

Still unverified

Selected primary abstracts only, not a systematic review or a complete scientific profile.
Test preparations have not been matched to any Treatfolio product, market, batch or package.
Study schedules are not consumer instructions; regulatory status and personal suitability require separate evidence.
Chemical identity, the complete current regulatory profile and finished-product effects remain unverified.